Clinical Study

Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy For Inoperable Stage II-IIIb Nsclc

Posted Date: Sep 28, 2020

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Radiation Oncology
  • Type of Study: Device

To compare the overall survival (OS) in patients with stage II-IIIB NSCLC after image guided, motion-managed photon radiotherapy (Arm 1) or after image guided, motion-managed proton radiotherapy (Arm 2) both given with concurrent platinum- based chemotherapy.

Criteria:

Untreated Histologically Or Cytologically Proven Diagnosis Of Non-Small Cell Lung Cancer Prior To Registration. Clinical Ajcc (7Th Ed.) Stage Ii-Iiib Medically Non-Operable Disease, Or Surgically Unresectable Disease, Or Patients Who Refuse Surgery; Patients Who Present With N2 Or N3 Disease And An Undetectable Nsclc Primary Tumor Also Are Eligible.

Keywords:

Proton Therapy, Lung Cancer, Radiation Therapy

For More Information:

Emily Daugherty, Md
513-584-4073
daugheec@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.